Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound-Reference-Cited by-同舟云学术

Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound

Published:2022-09-14 Issue:17 Volume:96 Page:
ISSN:0022-538X
Container-title:Journal of Virology
language:en
Short-container-title:J Virol

Author:

Anang Saumya¹²,Richard Jonathan³⁴,Bourassa Catherine³⁴,Goyette Guillaume³⁴,Chiu Ta-Jung⁵,Chen Hung-Ching⁵,Smith Amos B.⁵,Madani Navid¹²,Finzi Andrés³⁴^ORCID,Sodroski Joseph¹²^ORCID

Affiliation:

1. Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

2. Department of Microbiology, Harvard Medical School, Boston, Massachusetts, USA

3. Centre de Recherche du CHUM, Montreal, Quebec, Canada

4. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada

5. Department of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Abstract

CD4-mimetic compounds (CD4mcs) and conformational blockers like BMS-806 and BMS-529 (temsavir) are small-molecule inhibitors of human immunodeficiency virus (HIV-1) entry into host cells. Although CD4mcs and conformational blockers inhibit HIV-1 entry by different mechanisms, they both target a pocket on the viral envelope glycoprotein (Env) spike that is used for binding to the receptor CD4 and is highly conserved among HIV-1 strains.

Funder

HHS | National Institutes of Health

Gilead Sciences

Gouvernement du Canada | Canadian Institutes of Health Research

Canada Foundation for Innovation

Canada Research Chairs

Publisher

American Society for Microbiology

Subject

Virology,Insect Science,Immunology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/jvi.00636-22